In this issue:
Mitapivat for non transfusiondependent α- or β-thalassaemia
Long-term benefits of tagraxofusp in blastic plasmacytoid dendritic cell neoplasm
Pegcetacoplan vs. eculizumab in PNH
Impact of hypomethylating agent use on hospital and ED visits in high-risk MDS
Sutimlimab for cold agglutinin disease
Azacitidine ± pevonedistat in high-risk MDS/CMML/low-blast AML
Risks and unmet needs for children and young adults with MPNs
Peripherally inserted central venous catheters decrease CLABSIs
Molecular characterisation of triple-negative MPNs
Long-term safety and efficacy of ravulizumab in PNH
Please login below to download this issue (PDF)